The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor

Significance Here we report a synthetic lethal interaction between the epitranscriptomic modifier FTO and the tumor suppressor VHL. Notably, FTO inhibition reduced the growth of both HIF wild type and HIF-deficient tumors. These findings reveal an epitranscriptomic vulnerability of VHL-deficient cells and identify a potential HIF-independent therapeutic target for ccRCC tumors. Loss of the von Hippel–Lindau (VHL) tumor suppressor is a hallmark feature of renal clear cell carcinoma. VHL inactivation results in the constitutive activation of the hypoxia-inducible factors (HIFs) HIF-1 and HIF-2 and their downstream targets, including the proangiogenic factors VEGF and PDGF. However, antiangiogenic agents and HIF-2 inhibitors have limited efficacy in cancer therapy due to the development of resistance. Here we employed an innovative computational platform, Mining of Synthetic Lethals (MiSL), to identify synthetic lethal interactions with the loss of VHL through analysis of primary tumor genomic and transcriptomic data. Using this approach, we identified a synthetic lethal interaction between VHL and the m6A RNA demethylase FTO in renal cell carcinoma. MiSL identified FTO as a synthetic lethal partner of VHL because deletions of FTO are mutually exclusive with VHL loss in pan cancer datasets. Moreover, FTO expression is increased in VHL-deficient ccRCC tumors compared to normal adjacent tissue. Genetic inactivation of FTO using multiple orthogonal approaches revealed that FTO inhibition selectively reduces the growth and survival of VHL-deficient cells in vitro and in vivo. Notably, FTO inhibition reduced the survival of both HIF wild type and HIF-deficient tumors, identifying FTO as an HIF-independent vulnerability of VHL-deficient cancers. Integrated analysis of transcriptome-wide m6A-seq and mRNA-seq analysis identified the glutamine transporter SLC1A5 as an FTO target that promotes metabolic reprogramming and survival of VHL-deficient ccRCC cells. These findings identify FTO as a potential HIF-independent therapeutic target for the treatment of VHL-deficient renal cell carcinoma.

[1]  Laura E. Herring,et al.  TBK1 is a Synthetic Lethal Target in Cancer with VHL Loss. , 2019, Cancer discovery.

[2]  A. Ashworth,et al.  Synthetic lethality as an engine for cancer drug target discovery , 2019, Nature Reviews Drug Discovery.

[3]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[4]  N. Perrimon,et al.  HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species , 2019, Science Signaling.

[5]  Zhike Lu,et al.  m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade , 2019, Nature Communications.

[6]  Yanli Wang,et al.  Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1 , 2019, Science Translational Medicine.

[7]  Hualiang Jiang,et al.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.

[8]  Q. Lan,et al.  The Critical Role of RNA m6A Methylation in Cancer. , 2019, Cancer research.

[9]  Guohui Wan,et al.  RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3 , 2019, Molecular cancer.

[10]  C. Fan,et al.  VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma , 2018, Science.

[11]  James E. Bradner,et al.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling , 2018, Cell.

[12]  R. Figlin,et al.  Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Joe T. Sharick,et al.  Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models , 2017, Nature Medicine.

[14]  Francisco J. Sánchez-Rivera,et al.  Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.

[15]  Jacob D. Jaffe,et al.  HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase , 2017, Science Translational Medicine.

[16]  Subarna Sinha,et al.  Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data , 2017, Nature Communications.

[17]  G. Stephanopoulos,et al.  Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers , 2017, The Journal of clinical investigation.

[18]  Jie Jin,et al.  FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. , 2017, Cancer cell.

[19]  O. Razorenova,et al.  Rho-Associated Kinase 1 (ROCK1) inhibition is Synthetically Lethal with Von Hippel Lindau (VHL) Deficiency in Clear Cell Renal Cell Carcinoma (CC-RCC) , 2016, Oncogene.

[20]  K. Gardner,et al.  Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.

[21]  Hyejin Cho,et al.  On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models , 2016, Nature.

[22]  J. Chai,et al.  A Novel Inhibitor of the Obesity-Related Protein FTO. , 2016, Biochemistry.

[23]  Le Xu,et al.  High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma , 2015, Scientific Reports.

[24]  J. Brugarolas,et al.  High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma , 2015, Oncotarget.

[25]  Cheng Luo,et al.  Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5 , 2014, Nucleic acids research.

[26]  Eytan Ruppin,et al.  Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.

[27]  Xiaodong Cui,et al.  Exome-based analysis for RNA epigenome sequencing data , 2013, Bioinform..

[28]  G. Stephanopoulos,et al.  In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. , 2013, Cell metabolism.

[29]  P. Massion,et al.  SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival , 2012, Clinical Cancer Research.

[30]  Cheng Luo,et al.  Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. , 2012, Journal of the American Chemical Society.

[31]  C. Porta,et al.  Treatment selection in metastatic renal cell carcinoma: expert consensus , 2012, Nature Reviews Clinical Oncology.

[32]  Chengqi Yi,et al.  N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO , 2011, Nature chemical biology.

[33]  W. Kaelin,et al.  New insights into the biology of renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.

[34]  A. Giaccia,et al.  Harnessing synthetic lethal interactions in anticancer drug discovery , 2011, Nature Reviews Drug Discovery.

[35]  B. Rini.  Metastatic renal cell carcinoma: many treatment options, one patient. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[37]  W. Kaelin.  The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[38]  Robert Tibshirani,et al.  Boolean implication networks derived from large scale, whole genome microarray datasets , 2008, Genome Biology.

[39]  P. Sutphin,et al.  A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. , 2008, Cancer cell.

[40]  E. Rankin,et al.  The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.

[41]  Svetlana V. Harbaugh,et al.  The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress , 2008, Molecular and Cellular Biology.

[42]  Chris P. Ponting,et al.  The Obesity-Associated FTO Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase , 2007, Science.

[43]  P. Sutphin,et al.  Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. , 2007, Cancer research.

[44]  E. Cho,et al.  p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.

[45]  三原 忠紘,et al.  てんかん治療の Expert Consensus , 2004 .

[46]  Hongmei Wang,et al.  Tumor Suppressor von Hippel-Lindau (VHL) Stabilization of Jade-1 Protein Occurs through Plant Homeodomains and Is VHL Mutation Dependent , 2004, Cancer Research.

[47]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[48]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[49]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[50]  S. Elledge,et al.  Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.

[51]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[52]  R. Klausner,et al.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  O. Hankinson,et al.  The Role of the Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) in Hypoxic Induction of Gene Expression , 1996, The Journal of Biological Chemistry.

[54]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[55]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[56]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[57]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.